Okur-Chung neurodevelopmental syndrome

Summary

Okur-Chung neurodevelopmental syndrome (MONDO:0014893) is a disease caused by CSNK2A1 (GenCC Definitive), with 1 cohort gene.

At a glance

• Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
• Causal gene: CSNK2A1 (GenCC Definitive)
• Cohort genes: 1
• ClinVar variants: 78

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Cases/families		48	Worldwide	Validated
Point prevalence	<1 / 1 000 000		Worldwide	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	Okur-Chung neurodevelopmental syndrome
Mondo ID	MONDO:0014893
OMIM	617062
Orphanet	689422
UMLS	C4310739
MedGen	934706
GARD	0015008
Is cancer (heuristic)	no

Also known as: OCNDS · Okur-Chung neurodevelopmental syndrome · Okur-Chung neurodevelopmental syndrome; OCNDS

Data availability: 78 ClinVar variants · 4 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › hereditary neurological disease › Mendelian neurodevelopmental disorder › Okur-Chung neurodevelopmental syndrome

Related subtypes (275): microcephaly and chorioretinopathy, microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability, autosomal dominant primary microcephaly, Prader-Willi syndrome, Smith-Magenis syndrome, microcephalic osteodysplastic primordial dwarfism type I, microcephalic osteodysplastic primordial dwarfism type II, microcephalic osteodysplastic primordial dwarfism, type 3, CK syndrome, orofaciodigital syndrome I, Rett syndrome, Wieacker-Wolff syndrome, Amish lethal microcephaly, cerebral palsy, spastic quadriplegic, 2, Pitt-Hopkins-like syndrome 2, developmental delay with autism spectrum disorder and gait instability, complex cortical dysplasia with other brain malformations 5, AHDC1-related intellectual disability - obstructive sleep apnea - mild dysmorphism syndrome, intellectual disability, autosomal dominant 29, Au-Kline syndrome, cerebellar atrophy, visual impairment, and psychomotor retardation;, neurodevelopmental disorder with or without anomalies of the brain, eye, or heart, cerebral palsy, spastic quadriplegic, 3, Harel-Yoon syndrome, neurodevelopmental disorder with hypotonia, seizures, and absent language, alternating hemiplegia of childhood, autosomal recessive primary microcephaly, Rubinstein-Taybi syndrome, neurodevelopmental disorder with cerebellar atrophy and with or without seizures, neurodevelopmental disorder with or without autistic features and/or structural brain abnormalities, neurodevelopmental disorder with hypotonia, microcephaly, and seizures, neurodevelopmental disorder with hypotonia and cerebellar atrophy, with or without seizures, neurodevelopmental disorder and structural brain anomalies with or without seizures and spasticity, neurodevelopmental disorder with language impairment and behavioral abnormalities, neurodevelopmental disorder with seizures, hypotonia, and brain imaging abnormalities, neurodevelopmental disorder with microcephaly, impaired language, epilepsy, and gait abnormalities, neurodevelopmental disorder with dysmorphic facies, sleep disturbance, and brain abnormalities, neurodevelopmental disorder with cardiomyopathy, spasticity, and brain abnormalities, neurodevelopmental disorder with or without early-onset generalized epilepsy, neurodevelopmental disorder with or without autism or seizures, neurodevelopmental disorder with cerebral atrophy and variable facial dysmorphism, neurodevelopmental disorder with dysmorphic facies and variable seizures, squalene synthase deficiency, intellectual developmental disorder and retinitis pigmentosa; IDDRP, neurodevelopmental disorder with impaired intellectual development, hypotonia, and ataxia, Houge-Janssens syndrome 3, neurodevelopmental disorder with central and peripheral motor dysfunction, neurodevelopmental disorder with microcephaly, epilepsy, and hypomyelination, neurodevelopmental disorder with impaired speech and hyperkinetic movements, developmental delay with variable intellectual impairment and behavioral abnormalities, neurodevelopmental disorder with or without variable brain abnormalities; NEDBA, neurodevelopmental disorder with seizures and speech and walking impairment, neurodevelopmental disorder with microcephaly and structural brain anomalies, neurodevelopmental disorder with seizures and nonepileptic hyperkinetic movements, neurodevelopmental disorder with coarse facies and mild distal skeletal abnormalities, neurodevelopmental disorder with visual defects and brain anomalies, neurodevelopmental disorder with ataxia, hypotonia, and microcephaly, neurodevelopmental disorder with cataracts, poor growth, and dysmorphic facies, neurodevelopmental disorder with cerebellar hypoplasia and spasticity, neurodevelopmental disorder with structural brain anomalies and dysmorphic facies, neurodevelopmental disorder with hypotonia and variable intellectual and behavioral abnormalities, neurodevelopmental disorder with microcephaly, arthrogryposis, and structural brain anomalies, neurodevelopmental disorder with spastic quadriplegia, optic atrophy, seizures, and structural brain anomalies, neurodevelopmental disorder with dysmorphic facies and distal skeletal anomalies, neurodevelopmental disorder with absent language and variable seizures, neurodevelopmental disorder with nonspecific brain abnormalities and with or without seizures, neurodevelopmental disorder with behavioral abnormalities, absent speech, and hypotonia, neurodevelopmental disorder with microcephaly, cortical malformations, and spasticity, neurodevelopmental disorder with brain anomalies and with or without vertebral or cardiac anomalies, Poirier-Bienvenu neurodevelopmental syndrome, neurodevelopmental disorder with epilepsy, spasticity, and brain atrophy, neurodevelopmental disorder with hypotonia and autistic features with or without hyperkinetic movements, neurodevelopmental disorder with hypotonia, neonatal respiratory insufficiency, and thermodysregulation, neurodevelopmental disorder with microcephaly and dysmorphic facies, neurodevelopmental disorder with relative macrocephaly and with or without cardiac or endocrine anomalies, neurodevelopmental disorder with dysmorphic facies, impaired speech, and hypotonia, neurodevelopmental disorder with progressive spasticity and brain white matter abnormalities, neurodevelopmental disorder with speech impairment and dysmorphic facies, neurodevelopmental disorder with alopecia and brain abnormalities, neurodevelopmental disorder with seizures and brain atrophy, neurodevelopmental disorder with microcephaly, seizures, and brain atrophy, Delpire-McNeill syndrome, neurodevelopmental disorder with epilepsy, cataracts, feeding difficulties, and delayed brain myelination, developmental delay and seizures with or without movement abnormalities, Stankiewicz-Isidor syndrome, neurodevelopmental disorder with midbrain and hindbrain malformations, neurodevelopmental disorder with microcephaly, hypotonia, and variable brain anomalies, neurodevelopmental disorder with involuntary movements, neurodevelopmental disorder with hypotonia, neuropathy, and deafness, neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies, encephalopathy, neonatal severe, with lactic acidosis and brain abnormalities, neurodevelopmental disorder with microcephaly, ataxia, and seizures, neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizures, neurodevelopmental disorder with dysmorphic facies and distal limb anomalies, neurodevelopmental disorder with microcephaly, seizures, and cortical atrophy, neurodevelopmental disorder with severe motor impairment and absent language, neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter, neurodevelopmental disorder with microcephaly, epilepsy, and brain atrophy, neurodevelopmental disorder with or without seizures and gait abnormalities, neurodevelopmental disorder with movement abnormalities, abnormal gait, and autistic features, neurodevelopmental disorder with poor language and loss of hand skills, neurodevelopmental disorder with microcephaly, cataracts, and renal abnormalities, neurodevelopmental disorder with spastic quadriplegia and brain abnormalities with or without seizures, neurodevelopmental disorder with spasticity and poor growth, neurodevelopmental disorder with regression, abnormal movements, loss of speech, and seizures, neurodevelopmental disorder with epilepsy and hypoplasia of the corpus callosum, FOXG1 disorder, genetic developmental and epileptic encephalopathy, X-linked complex neurodevelopmental disorder, PPP2R1A-related intellectual disability, intellectual disability, autosomal dominant, CACNA1A-related complex neurodevelopmental disorder, X-linked intellectual disability, PAX5-related B lymphopenia and autism spectrum disorder, neurodevelopmental disorder with microcephaly, impaired language, and gait abnormalities, KCNH1 associated disorder, AFG2B-related complex neurodevelopmental disorder with motor features and hearing loss, intellectual disability, autosomal recessive, FAT4-related neurodevelopmental disorder, SOX11-related complex neurodevelopmental disorder with or without congenital anomalies, microcephaly with lissencephaly and/or hydranencephaly, MYH10-related neurodevelopmental disorder with congenital anomalies, CNOT9-related developmental disorder with seizures, HMGB1-related brachyphalangy, polydactyly and tibial aplasia syndrome, ATXN7L3-related developmental delay, hypotonia and facial dysmorphism, DIP2C-related developmental disorder with speech delay, EPB41L3-related developmental disorder with delayed myelination and seizures, GABRA4-related neurodevelopmental disorder with seizures, GABRD-related neurodevelopmental disorder with epilepsy, KCNK3-related developmental delay with sleep apnea, RFX3-related neurodevelopmental disorder with autism and other behavioural abnormalities, RFX4-related neurodevelopmental disorder with autism and other behavioural abnormalities, KDM2B-related neurodevelopmental disorder, TRA2B-related neurodevelopmental disorder, WDR5-related neurodevelopmental disorder, ARF3-related neurodevelopmental disorder, CBX1-related neurodevelopmental disorder, DDX17-related neurodevelopmental disorder, FEZF2-related neurodevelopmental disorder, HDAC3-related neurodevelopmental disorder, DEAF1-associated neurodevelopmental disorder, SYNCRIP-related neurodevelopmental disorder, HNRNPC-related neurodevelopmental disorder, NACC1-related neurodevelopmental disorder with epilepsy, cataracts and episodic irritability, SETD2-related neurodevelopmental disorder without or with macrocephaly/overgrowth, neurodevelopmental disorder with gait disturbance, dysmorphic facies, and behavioral abnormalities, X-linked, Alzahrani-Kuwahara syndrome, neurodevelopmental disorder with spasticity, cataracts, and cerebellar hypoplasia, neurodevelopmental disorder with dysmorphic facies and cerebellar hypoplasia, Hiatt-Neu-Cooper neurodevelopmental syndrome, neurodevelopmental disorder with seizures and gingival overgrowth, neurodevelopmental disorder with cerebellar atrophy and motor dysfunction, neurodevelopmental disorder with infantile epileptic spasms, neurodevelopmental disorder with hypotonia, facial dysmorphism, and brain abnormalities, neurodevelopmental disorder with motor and speech delay and behavioral abnormalities, neurodevelopmental disorder with dysmorphic facies and thin corpus callosum, neurodevelopmental disorder with hypotonia and dysmorphic facies, neurodevelopmental disorder with hypotonia and brain abnormalities, neurodevelopmental disorder with impaired language and ataxia and with or without seizures, neurodevelopmental disorder with hearing loss and spasticity, neurodevelopmental disorder with hypotonia and gross motor and speech delay, neurodevelopmental disorder with hyperkinetic movements and dyskinesia, neurodevelopmental disorder, nonprogressive, with spasticity and transient opisthotonus, Marbach-Schaaf neurodevelopmental syndrome, neurodevelopmental disorder with microcephaly, seizures, and neonatal cholestasis, Brunet-Wagner neurodevelopmental syndrome, Ferguson-Bonni neurodevelopmental syndrome, neurodevelopmental disorder with or without variable movement or behavioral abnormalities, neurodevelopmental disorder with central hypotonia and dysmorphic facies, neurodevelopmental disorder with neuromuscular and skeletal abnormalities, Chilton-Okur-Chung neurodevelopmental syndrome, neurodevelopmental disorder with hypotonia, impaired speech, and behavioral abnormalities, parenti-mignot neurodevelopmental syndrome, neurodevelopmental disorder with microcephaly, hypotonia, nystagmus, and seizures, Dentici-Novelli neurodevelopmental syndrome, neurodevelopmental disorder with poor growth and skeletal anomalies, neurodevelopmental disorder with language delay and seizures, neurodevelopmental disorder with dystonia and seizures, Dworschak-Punetha neurodevelopmental syndrome, neurodevelopmental disorder with epilepsy and brain atrophy, neurodevelopmental disorder with severe motor impairment, absent language, cerebral hypomyelination, and brain atrophy, neurodevelopmental disorder with speech delay and variable ocular anomalies, neurodevelopmental disorder with intention tremor, pyramidal signs, dyspraxia, and ocular anomalies, neurodevelopmental disorder with spasticity, seizures, and brain abnormalities, neurodevelopmental disorder with microcephaly, movement abnormalities, and seizures, neurodevelopmental disorder with seizures, microcephaly, and brain abnormalities, neurodevelopmental disorder with microcephaly, short stature, and speech delay, neurodevelopmental disorder with hypotonia, language delay, and skeletal defects with or without seizures, neurodevelopmental disorder with microcephaly, cerebral atrophy, and visual impairment, neurodevelopmental disorder with short stature, prominent forehead, and feeding difficulties, neurodevelopmental disorder with dysmorphic facies and skeletal and brain abnormalities, neurodevelopmental disorder with facial dysmorphism, absent language, and pseudo-pelger-huet anomaly, neurodevelopmental disorder with craniofacial dysmorphism and skeletal defects, neurodevelopmental disorder with eye movement abnormalities and ataxia, neurodevelopmental disorder with growth retardation, dysmorphic facies, and corpus callosum abnormalities, neurodevelopmental disorder with speech impairment and with or without seizures, neurodevelopmental disorder with hypotonia, dysmorphic facies, and skin abnormalities, neurodevelopmental disorder with poor growth, large ears, and dysmorphic facies, neurodevelopmental disorder with dysmorphic facies and ischiopubic hypoplasia, neurodevelopmental disorder with hypotonia, dysmorphic facies, and skeletal anomalies, with or without seizures, neurodevelopmental disorder with poor growth and behavioral abnormalities, neurodevelopmental disorder with seizures, spasticity, and complete or partial agenesis of the corpus callosum, neurodevelopmental disorder with absent speech and movement and behavioral abnormalities, neurodevelopmental disorder with language delay and behavioral abnormalities, with or without seizures, neurodevelopmental disorder with microcephaly and speech delay, with or without brain abnormalities, neurodevelopmental disorder with intracranial hemorrhage, seizures, and spasticity, neurodevelopmental disorder with motor and language delay, ocular defects, and brain abnormalities, neurodevelopmental disorder with microcephaly and movement abnormalities, neurodevelopmental disorder with hypotonia and speech delay, with or without seizures, neurodevelopmental disorder with dysmorphic facies and behavioral abnormalities, neurodevelopmental disorder with impaired language, behavioral abnormalities, and dysmorphic facies, neurodevelopmental disorder with language delay and variable cognitive abnormalities, neurodevelopmental disorder with motor regression, progressive spastic paraplegia, and oromotor dysfunction, Hao-Fountain syndrome due to USP7 mutation, neurodevelopmental disorder with motor abnormalities, seizures, and facial dysmorphism, neurodevelopmental disorder with hyperkinetic movements, seizures, and structural brain abnormalities, neurodevelopmental disorder with hypotonia and characteristic brain abnormalities, neurodevelopmental disorder with early-onset parkinsonism and behavioral abnormalities, Jeffries-Lakhani neurodevelopmental syndrome, neurodevelopmental disorder with language impairment, autism, and attention deficit-hyperactivity disorder, neurodevelopmental disorder plus optic atrophy, neurodevelopmental disorder with progressive movement abnormalities, aplasia cutis-enamel dysplasia syndrome, neurodevelopmental disorder with hypotonia and seizures, El Hayek-Chahrour neurodevelopmental disorder, neurodevelopmental disorder with hypotonia, feeding difficulties, facial dysmorphism, and brain abnormalities, neurodevelopmental disorder with hypotonia, brain anomalies, distinctive facies, and absent language, otofacial neurodevelopmental syndrome, neurodevelopmental disorder with characteristic facial and ectodermal features and tetraparesis 1, Kariminejad neurodevelopmental syndrome, Karayol-Borroto-Haghshenas neurodevelopmental syndrome, neurodevelopmental disorder with dysmorphic facies, absent speech and ambulation, and brain abnormalities, neurodevelopmental disorder with variable familial hypercholanemia, intellectual developmental disorder with polymicrogyria and seizures, neurodevelopmental disorder with speech or visual impairment and brain hypomyelination, neurodevelopmental disorder with microcephaly, absent speech, and hypotonia, neurodevelopmental disorder with hypotonia, poor growth, dysmorphic facies, and agammaglobulinemia, neurodevelopmental disorder with progressive spasticity and brain abnormalities, neurodevelopmental disorder with thin corpus callosum, hypotonia, and absent language, neurodevelopmental disorder with white matter abnormalities and gait disturbance, neurodevelopmental disorder with poor growth, seizures, and brain abnormalities, neurodevelopmental disorder with poor or absent speech, dysmorphic facies, and behavioral abnormalities, neurodevelopmental disorder with ataxia and brain abnormalities, neurodevelopmental disorder with dysmorphic facies, brain anomalies, and seizures, Li-Takada-Miyake syndrome, neurodevelopmental disorder with behavioral, ear, and skeletal abnormalities, Nil-Deshwar neurodevelopmental syndrome, Popov-Chang syndrome, neurodevelopmental disorder with achalasia, polyneuropathy, and alacrima, Dursun-Ozgul neurodevelopmental syndrome, neurodevelopmental disorder with growth impairment, quadriparesis, and poor or absent speech, neurodevelopmental disorder with speech delay and behavioral abnormalities, Harel-Tora neurodevelopmental syndrome, neurocardiorenal malformation syndrome, neurodevelopmental disorder with behavioral abnormalities and childhood-onset spastic paraplegia, neurodevelopmental disorder with early-onset seizures, facial dysmorphism, and behavioral abnormalities, neurodevelopmental disorder with structural brain abnormalities and craniofacial abnormalities, Ramond-Elliott neurodevelopmental syndrome, microcephaly, progressive, with simplified gyral pattern and cerebellar hypoplasia, neurodevelopmental disorder with hypotonia, epilepsy, and absent speech, neurodevelopmental disorder with speech delay, movement abnormalities, and seizures, neurodevelopmental disorder with spasticity, thin corpus callosum, and decreased brain white matter, neurodevelopmental disorder with congenital cardiac defects and variable renal and ocular abnormalities, neurodevelopmental disorder with seizures, hypotonia, and variable spasticity, PIP5K1C-related neurodevelopmental disorder, KCND2-related neurodevelopmental disorder with or without seizures, PRPF19-related neurodevelopmental disorder, CTR9-related neurodevelopmental disorder, CAMK2D-related neurodevelopmental disorder and dilated cardiomyopathy, PPFIA3-related neurodevelopmental disorder, dyneinopathy, MYCBP2-related developmental delay with corpus callosum defects, GRIN-related complex neurodevelopmental disorder, RNU5B-1 related neurodevelopmental disorder with seizures and joint laxity, TSEN2-related neurodevelopmental disorder with or without thrombotic microangiopathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

78 retrieved; paginated sample, class counts are floors:

23 likely pathogenic, 20 uncertain significance, 19 pathogenic, 11 pathogenic/likely pathogenic, 3 conflicting classifications of pathogenicity, 1 benign, 1 benign/likely benign

ClinVar	Variant (HGVS)	Gene	Classification	Review
1033456	NM_177559.3(CSNK2A1):c.376del (p.Gln126fs)	CSNK2A1	Pathogenic	criteria provided, single submitter
1172788	NM_177559.3(CSNK2A1):c.473A>G (p.Lys158Arg)	CSNK2A1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1327181	NM_177559.3(CSNK2A1):c.400C>T (p.Arg134Ter)	CSNK2A1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1329650	NM_177559.3(CSNK2A1):c.838C>T (p.Arg280Ter)	CSNK2A1	Pathogenic	criteria provided, multiple submitters, no conflicts
1690320	NM_177559.3(CSNK2A1):c.832C>T (p.Arg278Ter)	CSNK2A1	Pathogenic	criteria provided, single submitter
1709571	NM_177559.3(CSNK2A1):c.127C>T (p.Arg43Ter)	CSNK2A1	Pathogenic	criteria provided, single submitter
224790	NM_177559.3(CSNK2A1):c.593A>G (p.Lys198Arg)	CSNK2A1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
224796	NM_177559.3(CSNK2A1):c.140G>A (p.Arg47Gln)	CSNK2A1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
224797	NM_177559.3(CSNK2A1):c.824+2T>C	CSNK2A1	Pathogenic	no assertion criteria provided
224799	NM_177559.3(CSNK2A1):c.524A>G (p.Asp175Gly)	CSNK2A1	Pathogenic	no assertion criteria provided
224800	NM_177559.3(CSNK2A1):c.149A>C (p.Tyr50Ser)	CSNK2A1	Pathogenic	no assertion criteria provided
2506470	NM_177559.3(CSNK2A1):c.152G>A (p.Ser51Asn)	CSNK2A1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
2663860	NM_177559.3(CSNK2A1):c.572G>A (p.Arg191Gln)	CSNK2A1	Pathogenic	criteria provided, multiple submitters, no conflicts
280816	NM_177559.3(CSNK2A1):c.139C>G (p.Arg47Gly)	CSNK2A1	Pathogenic	criteria provided, single submitter
3340574	NM_177559.3(CSNK2A1):c.151A>C (p.Ser51Arg)	CSNK2A1	Pathogenic	criteria provided, single submitter
3359031	NM_177559.3(CSNK2A1):c.139C>T (p.Arg47Ter)	CSNK2A1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
3375742	NM_177559.3(CSNK2A1):c.79G>A (p.Glu27Lys)	CSNK2A1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
3385354	NM_177559.3(CSNK2A1):c.224dup (p.Lys76fs)	CSNK2A1	Pathogenic	criteria provided, multiple submitters, no conflicts
421395	NM_177559.3(CSNK2A1):c.468T>A (p.Asp156Glu)	CSNK2A1	Pathogenic	criteria provided, multiple submitters, no conflicts
432689	NM_177559.3(CSNK2A1):c.149A>G (p.Tyr50Cys)	CSNK2A1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
4531756	NM_177559.3(CSNK2A1):c.538G>A (p.Glu180Lys)	CSNK2A1	Pathogenic	criteria provided, single submitter
4819102	NM_177559.3(CSNK2A1):c.829_847del (p.Ser277fs)	CSNK2A1	Pathogenic	criteria provided, single submitter
4819106	NM_177559.3(CSNK2A1):c.254del (p.Leu85fs)	CSNK2A1	Pathogenic	criteria provided, single submitter
4849518	NM_177559.3(CSNK2A1):c.546T>G (p.Tyr182Ter)	CSNK2A1	Pathogenic	criteria provided, single submitter
522077	NM_177559.3(CSNK2A1):c.529G>A (p.Gly177Ser)	CSNK2A1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
619014	NM_177559.3(CSNK2A1):c.466G>C (p.Asp156His)	CSNK2A1	Pathogenic	criteria provided, single submitter
619015	NM_177559.3(CSNK2A1):c.1A>G (p.Met1Val)	CSNK2A1	Pathogenic	criteria provided, single submitter
817389	NM_177559.3(CSNK2A1):c.96del (p.Glu32fs)	CSNK2A1	Pathogenic	criteria provided, single submitter
975528	NM_177559.3(CSNK2A1):c.479A>G (p.His160Arg)	CSNK2A1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
984881	NM_177559.3(CSNK2A1):c.934C>T (p.Arg312Trp)	CSNK2A1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 4 · Orphanet: 1 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
CSNK2A1	Definitive	Autosomal dominant	Okur-Chung neurodevelopmental syndrome	4

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
CSNK2A1	Orphanet:528084	Non-specific syndromic intellectual disability

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
CSNK2A1	HGNC:2457	ENSG00000101266	P68400	Casein kinase II subunit alpha	gencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
CSNK2A1	Casein kinase II subunit alpha	Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	27.7×	0.036

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
CSNK2A1	Kinase	yes	2.7.11.1	Prot_kinase_dom, Ser/Thr_kinase_AS, Kinase-like_dom_sf

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
cortical plate	1
ganglionic eminence	1
ventricular zone	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
CSNK2A1	301	ubiquitous	marker	cortical plate, ganglionic eminence, ventricular zone

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
CSNK2A1	2,313

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
CSNK2A1	P68400	320

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 15. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK	1	2284.0×	0.003	CSNK2A1
WNT mediated activation of DVL	1	1427.5×	0.003	CSNK2A1
Condensation of Prometaphase Chromosomes	1	1038.2×	0.003	CSNK2A1
Receptor Mediated Mitophagy	1	1038.2×	0.003	CSNK2A1
Phosphorylation and nuclear translocation of the CRY:PER:kinase complex	1	815.7×	0.003	CSNK2A1
Maturation of hRSV A proteins	1	761.3×	0.003	CSNK2A1
Signal transduction by L1	1	519.1×	0.004	CSNK2A1
Synthesis of PC	1	407.9×	0.005	CSNK2A1
Regulation of CDH1 posttranslational processing and trafficking to plasma membrane	1	335.9×	0.005	CSNK2A1
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding	1	300.5×	0.005	CSNK2A1
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known	1	300.5×	0.005	CSNK2A1
SPOP-mediated proteasomal degradation of PD-L1(CD274)	1	228.4×	0.005	CSNK2A1
Regulation of PTEN stability and activity	1	184.2×	0.006	CSNK2A1
KEAP1-NFE2L2 pathway	1	120.2×	0.008	CSNK2A1
Regulation of TP53 Activity through Phosphorylation	1	117.7×	0.008	CSNK2A1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
regulation of chromosome separation	1	8426.0×	0.002	CSNK2A1
symbiont-mediated disruption of host cell PML body	1	5617.3×	0.002	CSNK2A1
positive regulation of aggrephagy	1	2808.7×	0.002	CSNK2A1
negative regulation of signal transduction by p53 class mediator	1	1203.7×	0.004	CSNK2A1
negative regulation of double-strand break repair via homologous recombination	1	624.1×	0.006	CSNK2A1
negative regulation of apoptotic signaling pathway	1	561.7×	0.006	CSNK2A1
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	1	401.2×	0.007	CSNK2A1
positive regulation of Wnt signaling pathway	1	383.0×	0.007	CSNK2A1
rhythmic process	1	251.5×	0.009	CSNK2A1
double-strand break repair	1	203.0×	0.009	CSNK2A1
positive regulation of protein catabolic process	1	203.0×	0.009	CSNK2A1
negative regulation of translation	1	195.9×	0.009	CSNK2A1
positive regulation of cell growth	1	183.2×	0.009	CSNK2A1
protein folding	1	103.4×	0.014	CSNK2A1
Wnt signaling pathway	1	99.7×	0.014	CSNK2A1
regulation of cell cycle	1	74.6×	0.018	CSNK2A1
protein stabilization	1	66.9×	0.018	CSNK2A1
DNA damage response	1	53.5×	0.022	CSNK2A1
positive regulation of cell population proliferation	1	33.6×	0.033	CSNK2A1
apoptotic process	1	28.7×	0.037	CSNK2A1
signal transduction	1	16.1×	0.062	CSNK2A1

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
CSNK2A1	FEDRATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
CSNK2A1	36	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
FEDRATINIB	4	CSNK2A1
RUXOLITINIB	4	CSNK2A1
PALBOCICLIB	4	CSNK2A1
BELUMOSUDIL	4	CSNK2A1
ABEMACICLIB	4	CSNK2A1
NINTEDANIB	4	CSNK2A1
SUNITINIB	4	CSNK2A1
MIDOSTAURIN	4	CSNK2A1
MITOXANTRONE	4	CSNK2A1
QUERCETIN	3	CSNK2A1
LINIFANIB	3	CSNK2A1
ALISERTIB	3	CSNK2A1
DOVITINIB	3	CSNK2A1
LESTAURTINIB	3	CSNK2A1
RUBOXISTAURIN	3	CSNK2A1
ENTOSPLETINIB	3	CSNK2A1
SILMITASERTIB	2	CSNK2A1
FISETIN	2	CSNK2A1
ELLAGIC ACID	2	CSNK2A1
CI-1040	2	CSNK2A1
MOLIBRESIB	2	CSNK2A1
SU-014813	2	CSNK2A1
ONVANSERTIB	2	CSNK2A1
TG100-115	2	CSNK2A1
R-406	2	CSNK2A1
TOZASERTIB	2	CSNK2A1
LUTEOLIN	2	CSNK2A1
BAICALEIN	2	CSNK2A1
CHROMOCARB	2	CSNK2A1
PF-00562271	1	CSNK2A1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
CSNK2A1	1,085	Binding:937, Functional:146, ADMET:2

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
CSNK2A1	2.7.11.1	non-specific serine/threonine protein kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
CSNK2A1	1,085

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
FEDRATINIB	4	CSNK2A1
RUXOLITINIB	4	CSNK2A1
PALBOCICLIB	4	CSNK2A1
BELUMOSUDIL	4	CSNK2A1
ABEMACICLIB	4	CSNK2A1
NINTEDANIB	4	CSNK2A1
SUNITINIB	4	CSNK2A1
MIDOSTAURIN	4	CSNK2A1
MITOXANTRONE	4	CSNK2A1
QUERCETIN	3	CSNK2A1
LINIFANIB	3	CSNK2A1
ALISERTIB	3	CSNK2A1
DOVITINIB	3	CSNK2A1
LESTAURTINIB	3	CSNK2A1
RUBOXISTAURIN	3	CSNK2A1
ENTOSPLETINIB	3	CSNK2A1
SILMITASERTIB	2	CSNK2A1
FISETIN	2	CSNK2A1
ELLAGIC ACID	2	CSNK2A1
CI-1040	2	CSNK2A1
MOLIBRESIB	2	CSNK2A1
SU-014813	2	CSNK2A1
ONVANSERTIB	2	CSNK2A1
TG100-115	2	CSNK2A1
R-406	2	CSNK2A1
TOZASERTIB	2	CSNK2A1
LUTEOLIN	2	CSNK2A1
BAICALEIN	2	CSNK2A1
CHROMOCARB	2	CSNK2A1
PF-00562271	1	CSNK2A1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	CSNK2A1
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 0.